EXPECT THE BEST OF BOTH WORLDS FROM YOUR LEFT ATRIAL APPENDAGE OCCLUDER.
LEFT ATRIAL APPENDAGE OCCLUSION (LAAO)
Left Atrial Appendage Occlusion (LAAO) with Amulet™ is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AFib).
Appendage anatomies come in many shapes and sizes and so should your stroke-prevention device. Built on a proven Amplatzer technology, the Amplatzer Amulet left atrial appendage (LAA) occluder utilizes a disc and lobe designed for complete occlusion of the LAA, the broadest size on the market today1 and enhanced ease of use.
DESIGNED TO COMPLETELY SEAL THE WIDEST RANGE OF LAA ANATOMY
- Flexible Nitinol braid allows the device to conform to different types of LAA anatomy
- Available in a wide range of sizes to seal LAAs with landing zones from 11 to 31 mm in diameter1
- Proximal device positioning allows for placement regardless of distal anatomy or existence of multiple distal lobes1
CONTROLLED DEVICE POSITIONING WITH MINIMAL STEPS
- Preloaded to streamline preparation
- Single piece cable designed for ease of device delivery and better control during deployment
- A waist between the disc and lob allows for more flexible placement within the LAA
AMPLATZER AMULET: SUPPORTED BY GUIDELINES, PROVEN BY DATA
AUTHORIZED BY ESC AF GUIDELINES
“LAA occlusion may be considered for stroke prevention in patients with AF and contra-indications for long-term oral anticoagulation treatment”— class IIb, level of evidence B.2
PROVEN SUPERIOR IN CLINICAL STUDIES
For Afib patients with a prior ICH, AMPLATZER Amulet is proven superior to medical management.3
RISK REDUCTION: AMPLATZER AMULET VS. MEDICAL MANAGEMENT
In a study of 302 patients, 151 were treated with Left Atrial Appendage Occlusion and 151 were treated with medical management.3
1. St. Jude Medical. (2012, October). AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Instructions for Use.
2. Angelozzi A, Renda G, et al. The Risk of Intracranial Hemorrhage with Anticoagulation in the Elderly – Estimates of Prevalence and Therapeutic Strategies. American College of Cardiology, 2015;
Available from: http://www.acc.org/latest-in-cardiology/articles/2015/12/21/12/59/the-risk-of-intracranial-hemorrhage-with-anticoagulation-in-the-elderly; Accessed June 6, 2018.
3. Kirchhof, P., Benussi, S., Kotecha, D., et. al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-2962.
4. Nielsen-Kudsk, J., Paaske Johnsen, S., Wester, P., Damgaard, D., Airaksinen, J., Lund, J., …Krieger, D. W. (2017). Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral hemorrhage: A propensity score matched follow-up study. EuroIntervention. doi:10.4244/EIJ-D-17-00201.